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Cancer comprises a group of heterogeneous diseases encompassing high rates of morbidity and mortality. Heterogeneity, which is a
hallmark of cancer, is one of the main factors related to resistance to chemotherapeutic agents leading to poor prognosis.
Heterogeneity is profoundly affected by increasing levels of ROS. Under low concentrations, ROS may function as signaling
molecules favoring tumorigenesis and heterogeneity, while under high ROS concentrations, these species may work as cancer
modulators due to their deleterious, genotoxic or even proapoptotic effect on cancer cells. This double-edged sword effect
represented by ROS relies on their ability to cause genetic and epigenetic modifications in DNA structure. Antitumor
therapeutic approaches may use molecules that prevent the ROS formation precluding carcinogenesis or use chemical agents
that promote a sudden increase of ROS causing considerable oxidative stress inside tumor mass. Therefore, herein, we review
what ROS are and how they are produced in normal and in cancer cells while providing an argumentative discussion about
their role in cancer pathophysiology. We also describe the various sources of ROS in cancer and their role in tumor
heterogeneity. Further, we also discuss some therapeutic strategies from the current landscape of cancer heterogeneity, ROS
modulation, or ROS production.
1. Introduction
Cancer is the second leading cause of death worldwide and
accounted for 8.8 million deaths in 2015. Lung, prostate,
colorectal, stomach, and liver cancer are the most common
types of cancer in men, while breast, colorectal, lung, cervix,
and stomach cancer are the most common among women
[1]. Cancer comprises a group of more than one hundred
malignancies characterized by distinguishing traits named
hallmarks of cancer which may be summarized as hyperpro-
liferation, angiogenesis, insensitivity to antigrowth factors,
resistance to apoptosis, migration, escape from destruction
by the immune system, inflammation, and genome instabil-
ity [2, 3]. However, hallmarks of cancer are studied as
collective characteristics of cancer cells (and the intermingled
stroma); individual cells within a given tumor often depicts
variability in these traits, hence conferring different patterns
of cellularity to tumors [4].
Although the breakthroughs in cancer therapy experi-
enced recently have considerably improved the quality of life
of the patients, many of them still succumb mainly due to
cancer complications, which in turn is occasioned by late
diagnosis, by the inefficiency of treatments, or by the
combination of these factors. Curiously, at the beginning of
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treatment, the majority of tumors exhibit a substantial
sensitivity to current traditional therapies, but often these
tumors relapse and anticancer drug resistance is established.
Resistance to chemotherapy is closely related to tumor
heterogeneity, a phenomenon that was long known but
underestimated or even neglected ever since, during the
management of cancer patients. The existence of distinct
subpopulations of cancer cells which differed regarding carci-
nogenesis, resistance to therapy, and metastatization capacity
was first documented by Heppner, Fidler, and their col-
leagues [5–9] in the 1970s and 1980s. Currently, a myriad
of evidence has pointed out the relevant role played by
“mosaicism” represented by heterogeneous populations each
one constituting a particular niche harboring numerous
genetically distinct subclones that differ in many aspects,
mainly in their sensitivities and also in their possible thera-
peutic targets [10]. Intratumor heterogeneity refers to a cellu-
lar mosaicism (heterogeneity) occurs within a tumor, while
intertumor heterogeneity relates to heterogeneity across
several different tumors. In this context, chemotherapy acts
not in all cells in a tumor mass, allowing the surveillance of
the refractory cells that will be responsible for the high mor-
bidity and mortality related to cancer relapses [4]. However,
where did cancer heterogeneity come from? Several hypoth-
eses have been proposed in an attempt to explain the mech-
anisms involved in the cancer heterogeneity, and all of
them are related, at least in part, to the prevalence of cancer
stem cell in tumor bulk, asymmetric division presented by
cancer cells, variations in the genetic signature, modulation
of gene expression, and posttranslational modifications [11].
Reactive oxygen species (ROS) are pleiotropic molecules
or free radicals (molecules containing one or more unpaired
electrons in the atomic or molecular orbitals) generated by a
myriad of complex mechanisms of which the most relevant is
the incomplete oxidative phosphorylation that occurs during
biomolecule catabolism, especially in the electronic transport
chain. Under homeostasis, the cells are protected from the
deleterious effects of ROS because they present enzymatic
systems responsible for dismantling these highly reactive
molecules or even antioxidant substances capable of inacti-
vating excessive ROS and in turn reducing their toxicity.
ROS overproduction, failures in the scavenging mechanisms,
or even the insufficiency of antioxidants may lead to ROS
accumulation culminating in oxidative stress, a state of a cell
which is characterized by the oxidation of essential biomole-
cules [12]. Previously, the orthodox view of ROS considered
them as mere by-products of respiration (that leaks from
the electron transport chain) which are naturally or patho-
logically produced (during pro- and antioxidant mechanisms
unbalance) and randomly interact with certain cellular
targets such as intracellular lipids, proteins, and DNA, lead-
ing to the accumulation of damaged (oxidized) and nonfunc-
tional biomolecules [13]. Currently, a myriad of evidences
indicates that ROS are important and pleiotropic signaling
molecules [13] actuating as a double-edged sword in physio-
logic (e.g., when hydrogen peroxide is required for cytokine,
insulin, growth factor, AP-1, and NF-kB signaling) and
pathologic processes such as neurodegenerative diseases,
carcinogenesis, and even cancer heterogeneity [14].
Although a broad range of studies are focused on cancer
cells per se, the noncancer cell also plays a crucial role in
tumor progression. Nonneoplastic cells associated with
tumors, such as cancer-associated fibroblasts (CAF), endo-
thelial cells, immune cells, adipocytes, and pericytes, produce
and accumulate large amounts of ROS, especially CAF. Some
solid tumors, in particular pancreatic, prostate, and breast
cancer, depict numerous CAFs in contrast to a scarce number
of these cells usually found in renal and brain cancers [15].
However, all these distinct cells (cancerous or not) associated
to peritumoral neoangiogenesis constitute the heterogenic
and desmoplastic tissue frequently found in several solid
tumors and related to poor prognosis. Desmoplasia creates
an auspicious microenvironment for tumor proliferation by
originating a hypoxic and acidic niche as well as generating
a mechanical stretch that is responsible for converting
fibroblast to myofibroblast that also contributes to cancer
heterogeneity and drug resistance [16]. Therefore, this
altered microenvironment is maintained by hypoxic and
acidic microenvironment associated with an oxidative stress
fueled by a high level of mitochondrial ROS production [17].
Therefore, herein, we review what are ROS and how they
are produced in normal and in cancer cells while providing
an argumentative discussion about their role in cancer path-
ophysiology. We also describe the various sources of ROS in
cancer cells and what is known about their role in tumor
heterogeneity. We also propose therapeutic strategies that
can preclude the tumor progression by modifying the micro-
environment and modulating ROS production as well as
promoting an improvement of therapeutic agents and, thus,
the efficacy of cancer treatment.
2. The ROS Chemistry
ROS are molecules that may be radicals such as superoxide
(O2
•−) and hydroxyl radical (•OH) or nonradicals such as
hydrogen peroxide (H2O2) and singlet oxygen (
1O2) derived
from oxygen (O2) that can readily oxidize other molecules
including lipids, amino acids, proteins, and nucleic acids
[18]. The electronic configuration of the oxygen diatom is
[2He4]2s42p8 with the first ten electrons placed into the σ,
σ∗, and π orbitals and two unpaired electrons each located
in a different π∗ antibonding orbital. Removal of an electron
from O2 results in a superoxide cation radical (O2
•+). In con-
trast, if a single electron is added, the product is the superoxide
anion radical (O2
•−) [14]. The anionic nature of O2
•− restricts
both its diffusibility throughout the cell and its reactivity
toward electron-rich substrates. A variety of intracellular
ROS are derived from superoxide (O2
•−), which is dismutaded
(converted) to hydrogen peroxide (H2O2) by superoxide dis-
mutases (SODs) [19]. In contrast to superoxide, hydrogen
peroxide is highly diffusible throughout the cells and reacts
with low pKa thiol groups or proteins containing transition
metals (e.g., [Fe–S] clusters). In fact, due to electrostatic
attraction, [Fe–S] clusters are the main cellular target of
(O2
•−)-mediated toxicity. The reduction of H2O2, catalyzed
by the transition metal, produces a high reactive hydroxyl
radical (OH•) [20], for which there is no antioxidant pro-
tection system. Thus, O2
•−/H2O2 overproduction leads to a
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whole series of radical chain reactions involving damage of
important biomolecules promoting oxidative stress.
Formation of ROS is strongly related to the emergence of
several human pathologic conditions such as atherosclerosis,
neurodegenerative diseases, and aging as well as certain types
of human cancers including lung, breast, and colon. ROS are
generated in organisms by γ, X, and UV radiation, biotrans-
formation of dietary chemicals, some diet components, for
example, transient metal ions and inflammatory reactions
during normal cellularmetabolism. The resulting disturbance
of the prooxidant/antioxidant balance leads to a condition of
oxidative stress, with subsequent oxidation of cellular compo-
nents, activation of cytoplasmic/nuclear signal transduction
pathways, modulation of gene and protein expression, and
alteration of activities of DNA and RNA polymerases [18].
3. Regulation of ROS Production
ROS can appear from numerous intracellular sources.
Among them, the most important are mitochondria,
NADPH oxidases, and other enzymes. In most cell types,
mitochondria are thought to be the main contributor to
intracellular ROS production [13]. More specifically, inside
the mitochondria, the electron transport chain complexes I
and III, which pump protons out of the inner mitochondrial
membrane, are the sites responsible for the major superoxide
production [21].
Oxidative phosphorylation in mitochondria involves four
electron-transporting complexes, besides a H+-translocating
ATP synthetic complex. The complexes I (NADH-ubiqui-
none oxidoreductase) and III (ubiquinol-cytochrome c
oxidoreductase), as said above, were shown to be responsible
for much of the superoxide production [22–24]. Mammalian
complex I is an assembly of proteins composed of 34 subunits
encoded by the nuclear DNA and seven subunits encoded by
the mitochondrial DNA (mtDNA). A series of electron
carriers that are evolutionarily conserved conduct electrons
derived from the initial oxidation of NADH through a series
of iron-sulfur centers to eventually reduce ubiquinone by a
mechanism that pumps protons from the mitochondrial
matrix to escape to the outside of the mitochondrial mem-
brane. This complex generates semiquinones that have been
identified as the probable electron donors for transforming
O2 into O2
−, although the mechanisms are not entirely known
yet [22, 25]. Nevertheless, there are two possible points where
oxygen could access electrons at the end of cofactor chain:
the flavin moiety and the quinine-binding site.
Complex III, in turn, reduces equivalents, generated in
complexes I and II and contained in ubiquinol, and transfers
them through reactions with cytochrome b, the Rieske iron-
sulphur protein, and cytochrome c1 to the final electron
acceptor cytochrome c [26]. During the mechanism opera-
tion of complex III, two species of semiquinones are also
generated. The Q-cycle mechanism proposed for the func-
tioning of the ubiquinol cytochrome c reductase starts with
ubiquinol donating one electron to the Rieske iron-sulphur
protein, producing a semiquinone in proximity to the outer
face of the inner membrane, which then reduces the first
cytochrome b heme (b1). The second cytochrome b heme
(bH) located closer to the matrix side of the membrane
accepts one electron from the first heme and reduces ubiqui-
none to form ubisemiquinone and, subsequently, with the
passage of another to form ubiquinol [27].
As the structure and the functional mechanisms of com-
plex I are still unclear, a proper manner to study complex I is
to inhibit it. This complex is inhibited by more than 60 differ-
ent family compounds [28], and the rotenone is the most
commonly used to inhibit ROS formation during reverse
electron transfer and to induce it during forwarding electron
transfer [29, 30]. The superoxide production is higher during
the reverse electron transfer from succinate to NAD+, while
the forward electron transfer is lower [31–34]. Complex I
inhibiting method also showed that an iron-sulfur cluster
could be the site of electron leak (in which oxygen ends up
capturing an electron, forming superoxides [29, 30, 35].
Structural modifications in complex I play a crucial role in
ROS production mechanism [26]. Mutations in mtDNA,
which are constitutive or caused by mtDNA damage, can
lead to these modifications, resulting in a variety of patho-
genesis and cell aging [36, 37]. A consequence triggered by
a domain alteration in the respiratory complexes is the
decrease of electron transfer activity, increasing ROS produc-
tion, and thus establishing a vicious cycle of oxidative stress
and energetic decline [38, 39]. This dysregulation of mito-
chondrial metabolism is considered to be one of the roots
of age-related degenerative diseases [37] and cancer.
Cancer cells accumulate alterations in mitochondrial
genome, dysregulations in mitochondrial respiration, and
increased ROS production, feeding back oxidative injuries
and maybe increasing mtDNA mutation rate [40]. Interest-
ingly, complex I genes usually present higher quantity of
mutations than the others in various tumors [41]. Depending
on the type of mutation, it can be acquired before or after
oncogenesis. So, in cancers, would the metabolic dysregula-
tion be the cause the oncogenesis or is it an effect of it? This
question remains on debate.
Another problem of mitochondrial ROS accumulation is
disruption of the aggregation of complexes I and III insti-
gated by lipid peroxidation. Progressive peroxidation of
mitochondrial phospholipids can induce pathophysiology
in the respiratory chain [42], especially a decreased activity
of complexes I and III [43, 44]. Taking into account that cells
differ in morphology, the quantities of vesicles, reticles,
organelles, and mitochondria, density, size, and cytoskeleton
arrangement, and their susceptibility to ROS damage may
also vary according to this. Mitochondria with a thin mem-
brane may be, for example, more susceptible to ROS effects
than one with a thicker membrane. As we can see, various
factors are proposed to influence ROS generation in mito-
chondria [21, 45]. However, knowledge about the in vivo reg-
ulation of mitochondrial oxidant production still has many
blank spaces to be filled.
NADPH oxidase (NOX), another important source of
ROS production, is a multisubunit enzyme that catalyzes
∙O2
− production by the reduction of O2 using NADPH as
the electron donor. The classical NADPH oxidase found in
neutrophils is composed of five subunits: p47phox, p67phox,
p40phox, p22phox, and gp91phox (catalytic subunit, also
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known as NADPH oxidase isoform 2 (NOX2)) [46, 47]. In
unstimulated cells, p47phox, p67phox, and p40phox are
found in the cytosol, whereas p22phox and gp91phox are in
the cell membrane, organized as a heterodimeric flavoprotein,
cytochrome b558. In a stimulated cell, however, p47phox is
phosphorylated and the cytosolic subunits form a complex
that translocates to the cell membrane and associates with
cytochrome b558 to assemble the active oxidase, which trans-
fers an electron from the substrate to O2, forming ∙O2
− [48].
Although NOX were originally considered as enzymes
present only in phagocytic cells involved in host defense
and innate immunity, more recent evidences indicate that
there is a whole family of NADPH oxidases, based on the
discovery of gp91phox homologs [49, 50]. These newly dis-
covered homologs, expressed in various tissues and involved
in many biological functions, are now known as the NOX
family of NADPH oxidases [51].
ROS produced by NOX are considered normal and
necessary. They have twomajor roles in this process. The first
one is microbial killing, and superoxide generated by NOX2
is required for the respiratory burst that occurs in phago-
cytes. The second role is associated with regulation of cell
signaling. Even so, ROS produced by NOX are capable of
specifically and reversibly reacting with proteins, altering
their activity, localization, and also half-life [52].
4. ROS and Cancer Heterogeneity
Implications of ROS in tumor heterogeneity still lack exten-
sive studies. While certain cancer types or cell subpopula-
tions benefit from ROS-based therapies, oxidative stress
potentially instigates unbecoming effects on other cells or
subpopulations. Both healthy and cancer cells may have
increased genetic instability and mutations possibly caused
by free ROS inside the cell or even in the cell niche. The
dynamic sequence of events and constant pressure for cell
readjustments eventually promote the evolution of resilient,
drug-resistant cells. It is questionable if mitochondrial
ROS-mediated mechanisms are the unique contributor to
cancer drug resistance, but its roles and modulation of meta-
bolic events may be central to the process and results. Cancer
cells usually have some alternative survival mechanisms, and
the mitochondrial dysfunction and genetic alterations may
facilitate some of these cell survival advantages, even in the
presence of drug targeting [53].
ROS also impact cancer stem cells. Just as only a small
subpopulation of cancer cells resist to therapies, a small
portion of cancer stem cells determine cell differentiation.
Considering ROS as a mutagenic agent, it can either block
self-renewal or stimulate stem cell differentiation [54], which
may, consequently, increase tumor heterogeneity. Intercon-
nected or parallel ROS signaling networks may also influence
cancer stem cells and thus cancer drug-resistant cells. Such
signaling via ROS occurs for example in FoxO, a family of
the Forkhead transcription factors, which is strictly regulated
by PI3K/Akt. The phosphorylation of FoxO transcription
factors 3 (FoxO3) by Akt leads to the FoxO3’s association
with 14-3-3 proteins and the FoxO3’s retention in the
cytoplasm. The sequestration of FoxO3 in the cytoplasm
decreases the transcription activity of FoxO3-targeted
genes such as SOD2 and catalase, culminating in the eleva-
tion of ROS [55].
Therefore, the ability to coordinately or independently
modulate a repertoire of ROS signaling networks that conflict
with cellular functions and processes is critical to the regula-
tion of ROS-mediated drug resistance [53].
5. Cancer Stem Cell and ROS
The raising of different intratumor subpopulations is attrib-
uted at least in part to a subset of stem cell-like populations
named cancer stem cells (CSC). Solé et al. suggest that these
CSC are genetically unstable and that this instability is deri-
vate from the loss of DNA repair mechanisms and cell-
cycle checkpoints [56]. A growing amount of evidences sug-
gest that CSC is closely related to the emergence of cancer
heterogeneity.
The CSC hypothesis suggests that a minor subpopulation
with stemness properties is responsible for the tumor growth
by giving rise to different subclones that are frequently asso-
ciated to intratumor heterogeneity [57]. Of note, another the-
ory to justify the cancer heterogeneity, known as the clonal
evolution model, asserts that a malignant cell accumulates
various hereditary changes over the time that implicates in
advantages or disadvantages to the cell, which is hence sub-
jected to natural selection. The tumor implementations take
place after the accumulation of several mutations in a single
cell. However, these hypotheses are not mutually exclusive
being complementary of each other [58].
Currently, there is a consensus that CSCs generate cancer
heterogeneity via their selective ability to maintain tumor
growth through the generation of new copies of themselves
before differentiation while originating other differentiated
high cycling cell [59, 60]. On the other hand, the stochastic
model argues that all malignant cells have the capability to
generate the intratumor heterogeneity constituting a hall-
mark of several cancers and are believed to be induced by
genetic and nongenetic mechanisms [61]. The genetic mech-
anism of cancer heterogeneity comprises direct DNA
alterations such as successive mutations or base deletions.
These alterations can be also interleaved with ROS which
have been increasingly implicated in the physiological regu-
lation of crucial developmental processes, biological
processes, from gene expression and protein translation to
protein-protein interactions, and so forth. Also, deep DNA
injuries are inconsistent with cell viability and frequently
are associated with apoptosis, contributing to eliminate
genetically abnormal cells and maintaining homeostasis
[62]. Thus, although mutations can lead to carcinogenesis,
other mechanisms are involved in cancer heterogeneity.
Many pieces of evidences have pointed that cancer cell
heterogeneity is epigenetically modulated, for instance by
the microenvironment. Hence, the expression of proteins
related to proliferation, migration and metastasis, apoptosis
resistance, and stemness would altogether be controlled by
epigenetic events such as DNA methylation, histone modifi-
cation, and polycomb, miRNA, and chromatin remodeling
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which in turn are tightly influenced by the cell niche favoring
the emergence of heterogeneity [63].
CSCs’ influence counterpoises the radiation-induced
ROS production by increased expression of free radical
scavengers, as reported for mouse and human breast
CSCs [64]. In opposition to the high proliferative cancer
cells, CSCs display very low levels of ROS, mainly due
to increased activity of the antioxidant machinery and
aerobic glycolysis. Leukemia stem cells (LSCs) are highly
vulnerable to increases in ROS levels [64, 65]. This ability
might selectively protect CSCs from ROS-mediated DNA
damage and hence explain their resistance to irradiation
treatments. Importantly, in vitro studies of drug-sensitive
tumor cell lines suggest that cancer cells might transiently
and reversibly acquire drug resistance, indicating that
drug resistance might not always be a stable trait [66].
Given that ROS may influence a vast array of biological
processes, and that we are limited in our knowledge of which
species of ROS are implicated in any given physiological set-
ting, it seems an immense challenge to explore how ROS
metabolism can be manipulated to generate stem cells and
influence stem cell fate [67]. Understated differences between
normal cells and CSCs in their sensitivity to ROS can be
exploited to target CSCs in therapy.
6. The Roles of ROS in Cancer Proliferation
A heterogenic cancer cell population may be developed
through stress selection such as hypoxia, lack of nutrients,
chronic inflammation, and immune system activation.
Tumors with a high degree of heterogeneity frequently dem-
onstrate a high resistance to chemotherapy due, at least in
part, to the large number of CSCs [68, 69]. Different molecu-
lar targets have been studied in order to identify which
therapy would be specific to resistant CSC, including oxida-
tive stress therapy and chronic inflammation, therapies to
reverse the quiescent state presented by CSC and therapies
aiming at DNA damage and efficient cell export of cytotoxic
agents. The CSCs, similar to normal stem cells, are quiescent,
slow-cycling cells with the lower level of intracellular ROS
when compared to typical high proliferative cancer cells
[64, 70]. It is known that low levels of ROS are critical for
the stemness of SCs and HSCs [71].
The biological effects of ROS and the mechanisms regu-
lating its level have been studied in cancer cells as a whole,
but little is known about these issues specifically in the CSC
population. Recent studies have associated ROS, c-Myc, and
β-catenin-dependent Wnt pathway, which regulate c-Myc,
as a model for tumor proliferation.
Wnt signaling is important in embryo development and
also controls homeostatic self-renewal in adult tissues [72].
Radioresistant breast cancer cells showed CSC-like proper-
ties and elevation of β-catenin. NS398, a cyclooxygenase 2
inhibitor, enhanced the radiosensitivity of these cells, which
may be partially be explained by the downregulating the
expression of β-catenin [73].
In cancer cells, ROS are principally generated by a high
rate metabolism in mitochondria, endoplasmic reticulum,
and cell membranes [74]. The metabolic phenotypes
observed in tumor cells are different from the normal tissue.
Unlike nontumor cells, most of the energetic supply of cancer
cells occurs through increasing rate of glycolysis followed by
oxidation of pyruvate in mitochondria, a phenomenon
known as Warburg effect [75, 76]. The glycolysis replaces at
least part of the oxidative phosphorylation for generation of
ATP in cancer cells. This metabolic switch is essential for
the cancer cells to adapt to hypoxic conditions with less mito-
chondrial defects and ROS production [77]. ROS are
involved in each stage of cancer development, including ini-
tiation, promotion, and progression [78]. The increase in
intracellular ROS in cancer cells may involve a diversity of
mechanisms. The intrinsic mechanism of increasing intracel-
lular ROS may result from the activation of oncogenes, inac-
tivation of tumor suppressor genes, high metabolism, and
mitochondrial dysfunction [78]. It is common in cancers
for metabolism to be very active under the drive of oncogenic
signals, for example, constitutively active mutant Ras, Bcr-
Abl, and c-Myc [79, 80]. The activation of c-Myc could
increase ROS without the induction of apoptosis, while the
treatment with antioxidant NAC decreased the number of
c-Myc-induced hMre11 signals and improved cell survival
after c-Myc activation. c-Myc is a transcriptional factor
related to cell proliferation and overexpression of this factor
has also been found in cervical carcinomas, leukemias,
lymphomas, colon, and testicular cancer [55, 81].
During the process of tumor metastasis, which is often
enabled by epithelial-mesenchymal transition (EMT) [82],
disseminated cancer cells would seem to require a self-
renewal capability, similar to that exhibited by stem cells, in
order to spawn macroscopic metastases. This raises the
possibility that the EMT process, which enables cancer cell
dissemination, may also impart a self-renewal capability to
disseminating cancer cells. Indeed, the metastatic process is
at least superficially similar to the processes that occur during
tissue repair and regeneration and enable adult stem cells to
abandon the tissue reservoirs, such as the bone marrow, enter
and survive in the circulation, and exit into secondary tissue
sites, where they proliferate, differentiate, and participate in
tissue reconstruction [83, 84]. Together, these various lines
of evidence suggested a possible link between less differenti-
ated stem cells and the mesenchymal-appearing cells gener-
ated by EMTs.
Mani et al. and Morel et al., established a crucial link
between passage through EMT and the acquisition of molec-
ular and functional properties of stem cells [85, 86].
In summary, ROS can induce Wnt signal, specifically
Wnt/β-catenin pathway. Wnt activates downstream signal-
ing molecules that stabilize and promote accumulation of
the β-catenin into the nucleus [87, 88]. Many Wnt ligands
have been reported to promote EMT and CSC activities in
various types of cancers [89, 90]. c-Myc is regulated by
Wnt/β-catenin pathway, and consequently, it can attribute
greater metastatic potential, CSC properties, and resistance
to chemotherapy (Figure 1).
By itself, a mutagenic agent, ROS possess the ability to
block self-renewal or stimulate differentiation of stem cells
[54]. Interconnected ROS signaling pathways can influence
cancer stem cells and cancer resistant cells. Thus, the
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ability to coordinate or independently modulate several
ROS signaling networks that interfere with cellular func-
tions and processes is critical for the regulation of ROS-
mediated drug resistance.
7. Oxidative Stress Inducing Genomic
Instability and Cancer
Genetic or genomic instability comprises a phenomenon
characterized by the high frequency of mutations that
occurred within the genome of a particular group of cells,
especially neoplastic cells, which has been called “facilitating
characteristics” that contributes to set up the hallmarks of
cancer while culminating on cancer heterogeneity [91]. The
thousands of mutations that characterize the process favor
the acquisition or elimination of DNA fragments leading to
structural alterations of chromosomes. Especially in cancer,
variations in the chromosomal number are a frequent occur-
rence as well. Both structural changes and variations in the
number of chromosomes are common occurrences in many
if not all types of cancers [92].
High ROS production and its subsequent accumulation
in cells or tissues may favor the interaction of these molecules
with DNA components, producing bases modification,
inducing inter- and intrastrand bindings or promoting
DNA-protein crosslinks leading carcinogenesis [93]. Several
examples of ROS-interacting modifications in biomolecules
are now recognized, for instance, (i) hydroxyl radicals may
react with pyrimidines and/or purines as well as chromatin
proteins (ii) or may interact with DNA, causing single-
and/or double-strand breaks resulting in base modifications
and genomic instability, respectively, all of which can cause
alterations in gene expression [94]. The leading oxidative
DNA damage products include those of 8-oxo-7,8-dihydroa-
denine (8-oxoAde), 8-oxo-7,8-dihydroguanine (8-oxoGua),
8-oxo-7,8-dihydro-2-deoxyguanosine (8-oxodG), and 5,6-
dihydroxy-5,6-dihydrothymine as well as the ring-open


























Figure 1: Quiescent and/or self-renewing stem cells display low levels of ROS due to their basal metabolism associated to an efficient
antioxidant machinery. ROS can result from increased metabolism associated with dysfunctional mitochondria, oncogene activation, or
cytokine/growth factor signaling that triggers ROS-producing enzymes: NADPH oxidases, cycloxygenases (COX), and lipoxygenases
(LOX). ROS-induced Wnt/β-catenin signal in cancer stem-like cells. The exposure to oxidative stress activates Wnt pathway and
upregulates c-Myc. In CSCs, c-Myc expression level varies from cell-to-cell contributing to cancer heterogeneity. Wnt activate
downstream signaling molecules that promote the stabilization and accumulation of the β-catenin in the nucleus and leading to EMT, a
hallmark of cancer.
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diamino-4-hydroxy-5-formamido-pyrimidine [18, 94]. The
8-oxoGua constitutes one of the most common products of
DNA lesions caused by ROS, because guanine is the most
susceptible to oxidation than other nucleobases [95] and
strongly implicated in all stages of carcinogenesis. Tissues
devoid of efficient machinery for ROS removal are particu-
larly vulnerable to develop mutagenesis and carcinogenesis
[96]. Exogenous ROS generators such as smoking or high
alcoholic consumption constitute important risk factors
since they increase by up to 50% the rate of formation of 8-
oxoGua adducts [97]. Furthermore, high rates of 8-oxoGua
are commonly observed in several inflammatory pathologies,
aging, accelerating telomere shortening, and even in neoplas-
tic tissue in vitro and also in lung, breast, or prostate cancer
patients when compared to healthy individuals [95]. Unre-
paired 8-oxoGua is potentially one of the most mutagenic
lesions among oxidatively modified DNA bases, due to its
pairing with A which will cause a GC →TA mutation [97].
These findings are suggestive that 8-oxoGua constitutes a
prominent candidate to serve as a reliable biomarker of
ROS-induced mutagenesis and tumorigenesis or even in
theranostics [18].
In addition to the discussion above, high levels of ROS
may still lead to 8-oxoGua accumulation in telomeres,
mainly because in humans these regions are typically consti-
tuted by 10–15 kb multiple repeated sequences composed by
in-tandem (TTAGGG)n hexanucleotide repeats [98]. The
presence of 8-oxoGua in telomeres inhibits telomerase
activity and decreases the binding of telomeric proteins to
the telomere sequence, leading to the disruption of telomere
length, precluding the maintenance of chromosomal-end
capping with several consequences to a vast variety of biolog-
ical process including ageing, cell death, carcinogenesis, and
chromosome instability [99, 100]. Further, telomeres are less
efficiently repaired than the other portions of the genome
[100]. It has been previously demonstrated that chromosome
instability occasioned by telomere dysfunction implies the
development of nuclear anomalies such as micronuclei
(MN), nucleoplasmic bridges (NPBs), and nuclear buds
(NBUDs) that constitute biomarker genotoxicity [99, 101].
8. Anticancer Therapy
Heterogeneity contributes negatively to anticancer therapies
since multicellularity may favor the emergence of subclones
or subpopulations of cells that are refractory to both
traditional or target therapies and even to radiotherapy.
Chemical reactivity distinguishes ROS from other signaling
molecules conferring peculiar characteristics which will later
be discussed. Low levels of ROS actively participate in the
complex mechanisms of control of cell proliferation and
differentiation, while excessive amounts may lead to impor-
tant cell damage or even to apoptosis. However, a cancerous
cell tolerates high levels of endogenous oxidative stress, both
in culture and in vivo when compared with their regular
counterparts, as a result of an aberrant regulation of redox
homeostasis and stress adaptation [102]. The previous study
demonstrated that preincubation of normal epithelial cells to
low but continuous levels of exogenous oxidants confers
cellular resistance to subsequent oxidative stress even at
higher concentrations, showing that cancer cells may adapt
to survive to oxidative microenvironments [102]. Since can-
cer cells actively produce and accumulate large amounts of
ROS, without suffering the acute and deleterious effects of
oxidation, we argue that intrinsic oxidative stress observed
in several tumors may exert selective pressure to enrich the
tumor bulk with a population of cells that are capable of
stress adaptation [102]. Thus, those cells capable of resisting
oxidative moiety tensions may originate ROS-resistant
daughter cells, and the proliferation of these high ROS-
resistant cells may also contribute to cancer heterogeneity.
Previously, Kong and colleagues proposed the “threshold
concept” in an attempt to discriminate normal from neoplas-
tic cells based on their differential ability in maintaining
homeostasis. The threshold concept argues that the cells
respond progressively to increasing concentrations of ROS,
oscillating from an adaptive proliferation, passing through
the equilibrium state, and finally, after the ROS level sur-
passes certain limits, the cells are eliminated by apoptosis
[103]. In normal cells, the mechanisms underlying ROS
scavenging, such as enzyme-based or direct antioxidant mol-
ecules, constitute an efficient protection system against
malignant transformation. In these cells, a sudden ROS rise,
referred as “over boost,” may trigger apoptosis, eliminating
this cell [103, 104]. Those cells that survive to oxidative insult
are presumably capable of acquiring adaptive mechanisms to
counteract the potential toxic effects of elevated ROS and to
promote cell survival pathway, and these cells usually consti-
tute neoplastic cells.
Based on the above exposition, what is the most effective
therapeutic approach to be used in the management of
cancer? Prooxidative or antioxidative therapies? The answer
for this issue may be much more complicated than it appears
to be.
Chemotherapy and radiotherapy are a primordial treat-
ment for several cancers and may be associated or not to
cytoreductive resection to eliminate all tumor cells. While
the ionizing radiation used in radiotherapy induces a primar-
ily and direct DNA damage, most of the mechanisms under-
lying chemotherapeutic agents involve ROS production, and
consequently promote oxidative damage [105]. Platinum-
based antineoplastics such as cisplatin, carboplatin, oxalipla-
tin, and several alkylating agents induce ROS production
[106]. Although these agents are proven to be quite useful
in tumor remission in initial chemotherapy, these drugs tend
to lose their effectiveness as soon as tumors acquire resis-
tance. Therefore, we propose here that in spite of the increase
in ROS production caused by a wide range of chemothera-
peutics, only part of cancerous cells are eliminated; the rem-
iniscent cells can repopulate the tumor and contribute to the
emergence of a new heterogenic and drug-resistant tumor.
Nuclear factor E2-related factor 2 (Nrf2), a transcription
factor that regulates multiple antioxidant and detoxifying
enzymes, is primarily involved in adaption to various cellular
threatening situations including ROS-mediated stresses
[107]. Adaptive stress responses occurring in certain tumor
cells may include the activation of redox-sensitive Nrf2, pro-
moting an increase in the expression of ROS-scavenging
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enzymes, increasing the levels of prosurvival factors and
inhibiting cell death factors. Notwithstanding, the knock-
down of Nrf2 in endometrial serous carcinoma, a hetero-
geneous and highly resistant type of cancer, sensitized
Nrf2-overexpressing cells to chemotherapy [108]. These
findings suggest that therapy aiming at Nrf2 inhibition may
preclude cell proliferation while sensitizing the neoplastic
cells to apoptosis. Therefore, therapeutic regimens based on
the Nrf2 inhibition can become the frontline in cancer
management, especially for tumors with a high level of
expression of Nrf2 [108].
Epigenetics comprise stable heritable traits of chromo-
somes without alteration of the DNA sequence by itself
[97]. A growing amount of evidences has indicated that in
addition to genetic aberrations, epigenetic modifications
directly contribute to cancer heterogeneity and drug
resistance, and ROS plays a critical role in the mechanisms
underlying epigenetic regulation. Epigenetics disorders have
been identified in either cell culture or even in vivo especially
in tumors with a high degree of heterogeneity. In fact, it con-
stitutes a novel paradigm in cancer biology which posits that
tumors are composed of different cell populations, named
cancer cells (CS) and cancer stem cells (CSC), besides the
noncancerous cells, frequently found in the tumor bulk as
previously mentioned [109]. Although other epigenetic
changes may also occur, global hypomethylation, particu-
larly at centrometric repeats, and hypermethylation, often
occurring in CpG islands, are frequently present in cancer
[110, 111]. In this scenario, the use of drugs that interfere with
mechanisms of methylation control, especially demethylat-
ing agents, may have an important contribution to anti-
cancer therapy. Two classes of demethylating agents are
currently available: nucleoside DNMT inhibitors such as
5-azacytidine (azacitidine) and its derivate 5-aza-2′-deoxy-
cytidine (decitabine (DAC)) and nonnucleoside DNMT
inhibitors such as hydralazine, a vasodilator used as an
antihypertensive agent, procaine, a local anesthetic,
epigallocatechin-3-gallate (EGCG), the main polyphenol
constituent of green tea, and MG98, a second generation
of DNMT. Indeed, the use of these agents for cancer treat-
ment is not a brand new idea. The first demethylating
agent, 5-azacythidine (4-amino-1-β-D-ribofurnosyl-1,3,5-
triazin-2-one), a nucleoside pyrimidine-derivate analog,
was first synthesized about 40 years ago in Prague, Czech
Republic, and has since demonstrated remarkable biologi-
cal effects including modulation of cell differentiation
and cytostatic activity in various types of cancer [112].
Therefore, although these agents have been known for a
long time, only two inhibitors of DNA methyltransferases,
5-azacytidine (Vidaza) and 5-aza-2-deoxycytidine (decita-
bine), a cytidine analog, with better specificity, remarkable
inhibition of DNA methylation, and less toxic effects than
5-azacytidine, have already been approved by the FDA as
effective drugs for treatment of myelodysplastic syndromes
[12, 113]. Another cytidine-analog nucleoside, Zebularine
have been widely investigated basically because it is more sta-
ble than 5-azacytidine and decitabine [12]. Among the non-
nucleoside DNMT agents, EGCG stands out as a prominent
candidate for cancer therapy due to their ability to bind and
block the active site of DNMT1. Interestingly, the degrada-
tion of EGCG generates considerable amounts of hydrogen
peroxide that may contribute to cell death [114].
9. Concluding Remarks
Accumulative evidences have been proven that ROS are not
merely by-products of respiration. In addition to acting in
the signaling process, these molecules play a crucial role dur-
ing physiological and pathological events including aging,
neurodegenerative diseases, and cancer. In recent years, the
canonical role of ROS in genetic and genomic instability has
been extensively studied, but these studies do not respond to
certain aspects of the dynamics of cancer, especially those
related to epigenetics. These findings have provided a global
initiative to disclose the epigenetics mechanisms underlying
carcinogenesis and cancer heterogeneity. In contrast to
genetic mutations, epigenetics aberrations constitute revers-
ible events which may be restored to their normal state
through the application of epigenetic therapy, suggesting the
outstanding and promising potential of epigenetic drugs for
druggability. Furthermore, the tumormicroenvironment also
plays a very important role in carcinogenesis since nontumor
cells provide a niche that favors the onset ofCSC,which lead to
heterogeneity, drug resistance, and poor prognosis. Therefore,
although anticancer therapies employing classical cytotoxic
agents remain in use, epigenetic drugs, which may include
substances thatmodulate REDOX-state, should be considered
as an important alternative in monotherapy or even in
combination with other drugs.
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